Can Of Soup Weight, Logan Hampton Tn, Can A 16-year-old Get Their Own Car Insurance, Tempest Staff Dai, Maximum Permissible Error For Weighing Scales, Losing It Nevershoutnever Ukulele Chords, Happy Pills Nightcore Id Code, Toddler Lunch Ideas For Daycare, " /> Can Of Soup Weight, Logan Hampton Tn, Can A 16-year-old Get Their Own Car Insurance, Tempest Staff Dai, Maximum Permissible Error For Weighing Scales, Losing It Nevershoutnever Ukulele Chords, Happy Pills Nightcore Id Code, Toddler Lunch Ideas For Daycare, " />Can Of Soup Weight, Logan Hampton Tn, Can A 16-year-old Get Their Own Car Insurance, Tempest Staff Dai, Maximum Permissible Error For Weighing Scales, Losing It Nevershoutnever Ukulele Chords, Happy Pills Nightcore Id Code, Toddler Lunch Ideas For Daycare, " />

akebia therapeutics address

Akebia Therapeutics, Inc. () Stock Market info Recommendations: Buy or sell Akebia Therapeutics stock? If we look at who the major shareholders are, we find that insiders hold 3.18% of Akebia Therapeutics, Inc. shares while 78.98% of the shares are in the hands of institutional holders. Got it! CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies … are currently affected by chronic kidney disease. You are leaving akebia.com, a website of Akebia Therapeutics, Inc. Akebia does not review or control the content of non-Akebia websites, and this hyperlink does not constitute an endorsement by Akebia of the site’s content. Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Akebia Therapeutics, Inc. AKBA was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too … Akebia Therapeutics had a negative net margin of 113.35% and a negative return on equity of 55.64%. By continuing to use this website you agree to our use of cookies. Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -3.24% from its latest closing price compared to the recent 1-year high of $13.71. Akebia Therapeutics, Inc. is a Vermont Foreign Profit Corporation filed on October 22, 2020. We use cookies in order to provide you with a better browsing experience. About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia Therapeutics Inc (NASDAQ:AKBA) has been given an average rating of "Buy" by the ten analysts that are covering the company, Marketbeat.com reports. The share float percentage for the stock currently stands at 81.57%. We are a fully integrated biopharmaceutical company. +1 617.871.2099  fax. Akebia Therapeutics Inc. said its investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor vadadustat reached primary and key secondary efficacy endpoints in … The Registered Agent on file for this company is C T Corporation System and is located … Akebia Therapeutics, Inc. manufactures biopharmaceutical products. According to Zacks, "Akebia Therapeutics Inc. is a biopharmaceutical company. Cambridge, MA 02142 +1 617.871.2098 phone +1 617.871.2099 fax. Akebia Therapeutics. Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Our team works to address complications of kidney disease. Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a … The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. Needham & Company LLC began coverage on Akebia Therapeutics in a report on Tuesday, August 11th. Create Job Alert Cancel. © 2020 Akebia Therapeutics, Inc. All rights reserved. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. See insights on Akebia Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference, Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™, Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials, Akebia Therapeutics, Inc. 245 First Street, Suite 1400 Cambridge, MA 02142, +1 617.871.2098  phone +1 617.871.2099  fax. You are leaving akebia.com, a website of Akebia Therapeutics, Inc. Akebia does not review or control the content of non-Akebia websites, and this hyperlink does not constitute an endorsement by Akebia of the site’s content. close Create Job Alert. Vadadustat is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for use outside of Japan. See insights on Akebia Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. The average twelve-month pri Note Regarding Forward Looking Statements. AKBA has been the subject of a number of other research reports. The company's filing status is listed as Active and its File Number is 0379092. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Address. BidaskClub upgraded shares of Akebia Therapeutics (NASDAQ:AKBA) from a sell rating to a hold rating in a research note issued to investors on Thursday morning, BidAskClub reports. Akebia Therapeutics Inc.’s Net Margin is presently recorded at -83.48. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. Join Us! Akebia Therapeutics Inc. [AKBA]: Deeper insight into the fundamentals. Akebia Therapeutics, Inc. is a Massachusetts Foreign Corporation filed on December 12, 2013. Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -10.69% from its latest closing price compared to the recent 1-year high of $13.71. Akebia’s privacy procedures do not apply to the owners of a non-Akebia website. The company's filing status is listed as Active and its File Number is 0379092. Create Job Alert Cancel. Akebia Therapeutics, Inc. is a Massachusetts Foreign Corporation filed on December 12, 2013. The Registered Agent on file for this company is C T Corporation System and is located … For more information, please visit our website at www.akebia.com. Operating Margin for any stock indicates how profitable investing would be, and Akebia Therapeutics Inc. [AKBA] shares currently have an operating margin of -85.46 and a Gross Margin at +56.61. Akebia Therapeutics. See the company profile for Akebia Therapeutics, Inc. (AKBA) including business summary, industry/sector information, number of employees, business … We use cookies in order to provide you with a better browsing experience. Akebia Therapeutics, Inc. manufactures biopharmaceutical products. Akebia Therapeutics (NASDAQ:AKBA) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Friday, Zacks.com reports. Akebia Therapeutics, Inc. Tab l e of C on te n ts P ar t I . Akebia Therapeutics, Inc. is an Alaska Business Corporation filed on October 27, 2020. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat, in global Phase 3 clinical development for the treatment of anemia due to CKD. Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science. Operating Margin for any stock indicates how profitable investing would be, and Akebia Therapeutics Inc. [AKBA] shares currently have an operating margin of -85.46 and a Gross Margin at +56.61. Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s Major holders. Akebia Therapeutics. 33 Akebia Therapeutics jobs including salaries, ratings, and reviews, posted by Akebia Therapeutics employees. For all general inquiries, please contact: For employment verification, please visit Truework. The Registered Agent on file for this company is The Corporation Company and is located at 7700 E. Arapaphoe Road Suite 220, Centennial, CO 80112. The company’s stock price has collected -30.19% of loss in the last five trading sessions. The company’s stock price has collected 0.85% of gains in the last five trading sessions. We are bold and optimistic as we work to better the life of each person impacted by kidney disease. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. Akebia Therapeutics - Found 11 - 50 Employees, 6 Phone Numbers and 5 Emails. The … With this latest performance, AKBA shares dropped by -75.81% in over the last four-week period, additionally sinking by -67.29% over the last 6 months – not to mention a drop of -44.53% in the past year of trading. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Legal Business Name: AKEBIA THERAPEUTICS, INC. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Akebia Therapeutics has 324 employees at their 1 location and $335 M in annual revenue in FY 2019. Akebia Therapeutics, Inc. AKBA was a big mover last session, as the company saw its shares rise nearly 7% on the day. Press Release reported on 10/12/20 that Thinking about buying stock in Akebia Therapeutics, Aileron Therapeutics, Riot Blockchain, Plug Power, or Translate Bio? Akebia Therapeutics Inc. [AKBA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -16.61. Note Regarding Forward Looking Statements. Akebia Therapeutics has 324 employees at their 1 location and $335 M in annual revenue in FY 2019. Akebia Therapeutics, Inc. 245 First Street, Suite 1400. Akebia’s privacy procedures do not apply to the owners of a non-Akebia website. Do … search. Press Release reported on 10/12/20 that Thinking about buying stock in Akebia Therapeutics, Aileron Therapeutics, Riot Blockchain, Plug Power, or Translate Bio? Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -2.20% from its latest closing price compared to the recent 1-year high of $13.71. search. Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -3.24% from its latest closing price compared to the recent 1-year high of $13.71. Got it! Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.23. Search Business Operations. Akebia Therapeutics Inc.’s Net Margin is presently recorded at -83.48. 12 talking about this. The Registered Agent on file for this company is C T Corporation System and is located … The move came on solid volume too … Show search filters Clear filters. Emerging growth company ☐ Akebia Therapeutics Inc. 245 1st St CAMBRIDGE MA 02142-1200 P: +1617.8712098 F: +1617.8712099 Description. Akebia Presents Results from INNO2VATE Global Phase 3 Program for Vadadustat at ASN Kidney Week, As a member of the renal community, the health of our patients and employees is our first priority. +1 617.871.2098  phone For all general inquiries, please contact: close Create Job Alert. The company's File Number is listed as 208756903. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. Search job openings at Akebia Therapeutics. Phone. Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ November 16, 2020 Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials 1-617-871-2098. READ OUR COMPANY STATEMENT (8.10.20). Akebia Therapeutics Inc. [AKBA]: Deeper insight into the fundamentals. Akebia Therapeutics - Found 11 - 50 Employees, 6 Phone Numbers and 5 Emails. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. To learn more and to turn off cookies visit our Cookie Policy. For patients in the U.S. taking a prescribed Akebia product, please visit AkebiaCares.com or call 855-686-8601 for assistance. Chronic kidney disease is a serious and life-altering illness that is persistent, progressive, and irreversible. Search jobs by category. This dataset includes 357 thousand attorneys registered with New York State, Office of Court Administration. CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies … The company’s stock price has collected 0.85% of gains in the last five trading sessions. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia … Search jobs by category. CAMBRIDGE, Mass., Nov. 3, 2020-- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 6 newly-hired employees options to purchase an aggregate of 27,000 shares of Akebia's common stock on October 30, 2020, as inducements material to each such employee's entering into employment with Akebia. The company's filing status is listed as Good Standing and its File Number is 20131708174. The Cambridge, Massachusetts-based company said it had a loss of 42 cents per share. Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference November 18, 2020 Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ Join Us! Emerging growth company ☐ Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science. Get the latest Akebia Therapeutics, Inc. (AKBA) stock news and headlines to help you in your trading and investing decisions. Akebia Therapeutics, Inc. is a Vermont Foreign Profit Corporation filed on October 22, 2020. AKBA Akebia Therapeutics Inc Current Report Filing (8-k) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).. Kristen K. Sheppard, Esq VP, Investor Relations, Mercedes Carrasco Director, Corporate Communications media@akebia.com, Patrick Walsh VP, Business Development partnering@akebia.com, Susan Brady Manager, Advocacy & Corporate Communications sponsorships@akebia.com, Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference, Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™, Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials, Akebia Therapeutics, Inc. 245 First Street, Suite 1400 Cambridge, MA 02142, +1 617.871.2098  phone +1 617.871.2099  fax. CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies … Akebia Therapeutics. Akebia Therapeutics, Inc. is a Colorado Foreign Corporation filed on December 10, 2013. Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. The … Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease. © 2020 Akebia Therapeutics, Inc. All rights reserved. Search jobs by location. Show search filters Clear filters. Address: 10151 CARVER RD STE 205 CINCINNATI OHIO 45242 UNITED STATES: Congressional District The company's File Number is listed as 208756903. The company’s stock price has collected -23.24% of loss in the last five trading sessions. On average, equities research analysts expect that Akebia Therapeutics will post -1.5 earnings per share for the current fiscal year. Press Release reported 16 hours ago that Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights The analysts might have been a bit too bullish on Akebia Therapeutics, Inc. (NASDAQ:AKBA), given that the company fell short of expectations when it released its third-quarter results last week. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. F i n an c i al I n for mati on Item 1 – Financial Statements (Unaudited) Condensed Consolidated Balance Sheets … Each attorney is registered with registration number, full name, company name and address, phone number, email, year admitted, etc. Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for patients with chronic kidney disease.

Can Of Soup Weight, Logan Hampton Tn, Can A 16-year-old Get Their Own Car Insurance, Tempest Staff Dai, Maximum Permissible Error For Weighing Scales, Losing It Nevershoutnever Ukulele Chords, Happy Pills Nightcore Id Code, Toddler Lunch Ideas For Daycare,

Share This:

Tags:

Categories: